PR Newswire - Guangzhou Lupeng/Newave Pharmaceutical Inc. Enroll...
Head-to-Head Study Highlights Rocbrutinib as the World's First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations GUANGZHOU, China and SAN FRANCIS...
Read More

ภาษาไทย
English